SG11201901071TA - Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same - Google Patents
Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising sameInfo
- Publication number
- SG11201901071TA SG11201901071TA SG11201901071TA SG11201901071TA SG11201901071TA SG 11201901071T A SG11201901071T A SG 11201901071TA SG 11201901071T A SG11201901071T A SG 11201901071TA SG 11201901071T A SG11201901071T A SG 11201901071TA SG 11201901071T A SG11201901071T A SG 11201901071TA
- Authority
- SG
- Singapore
- Prior art keywords
- heterodimeric
- region
- protein
- fused
- physiologically active
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 239000000833 heterodimer Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 12
- 108090000623 proteins and genes Proteins 0.000 abstract 12
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000001766 physiological effect Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Abstract
Englishtranslation PCT/KR/008676 CONFIDENTIAL - 75 - G G The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus 5 or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein. The heterodimeric Fc-fused protein according to the present invention has an advantage in that it can retain the activity of a 10 naturally occurring physiologically active protein whose two or more different subunits exhibit physiological activity by forming a protein complex, because the physiologically active protein can be linked to an immunoglobulin heterodimeric Fc such that the naturally occurring form and structure of the fused protein thereof can be maintained. When the heterodimeric Fc-fused protein according to the present invention is used, there is an 15 advantage in that the in vivo half-life of the physiologically active protein contained in the heterodimeric Fc-fused protein can be significantly increased due to the Fc-mediated long half-life such that various physiological activities thereof in vivo can be long-lasting. Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same [Fig. 2]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160101823 | 2016-08-10 | ||
| KR1020170101594A KR102050463B1 (en) | 2016-08-10 | 2017-08-10 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| PCT/KR2017/008676 WO2018030806A1 (en) | 2016-08-10 | 2017-08-10 | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901071TA true SG11201901071TA (en) | 2019-03-28 |
Family
ID=61524969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901071TA SG11201901071TA (en) | 2016-08-10 | 2017-08-10 | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10696722B2 (en) |
| EP (1) | EP3511340A4 (en) |
| JP (3) | JP6993403B2 (en) |
| KR (4) | KR102050463B1 (en) |
| CN (1) | CN110267977A (en) |
| AU (2) | AU2017310163B2 (en) |
| CA (1) | CA3033475A1 (en) |
| MX (2) | MX2019001651A (en) |
| SG (1) | SG11201901071TA (en) |
| ZA (1) | ZA201900772B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3511340A4 (en) | 2016-08-10 | 2020-03-18 | Ajou University Industry-Academic Cooperation Foundation | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
| EP3649147A4 (en) | 2017-07-03 | 2021-04-14 | Torque Therapeutics, Inc. | Polynucleotides encoding immunostimulatory fusion molecules and uses thereof |
| CN111356524B (en) | 2018-02-14 | 2022-03-15 | 株式会社Lg化学 | Catalyst filling method and method for preparing butadiene using the same |
| CN110396133B (en) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | Fusion protein type prodrug with interleukin 12 as active component |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| WO2020086758A1 (en) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
| CN115916233A (en) * | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | Targeting IL-12 heterodimeric Fc fusion proteins |
| AU2021397322A1 (en) * | 2020-12-10 | 2023-07-06 | Invenra Inc. | Orthogonal mutations for heterodimerization |
| CA3234552A1 (en) * | 2021-10-20 | 2023-04-27 | Synthekine, Inc. | Heterodimeric fc cytokines and uses thereof |
| KR20230157760A (en) * | 2022-05-10 | 2023-11-17 | 아주대학교산학협력단 | Interleukin21 Variant and Fusion Protein Comprising the Same and Uses Thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP1037927B1 (en) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| US20020055488A1 (en) | 2000-09-21 | 2002-05-09 | Wessels Michael R. | Prevention and treatment of streptococcal and staphylococcal infection |
| US8192744B2 (en) | 2002-08-26 | 2012-06-05 | Ibcc Holding As | Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation |
| US20070259380A1 (en) | 2004-05-20 | 2007-11-08 | Kyoichi Sumida | Method for Measuring Hyaluronic Acid Using Hyaluronic Acid Binding Protein |
| CA2610791C (en) | 2005-06-08 | 2015-12-01 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| AU2007229698B9 (en) | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2008018519A1 (en) | 2006-08-08 | 2008-02-14 | Seikagaku Corporation | Method for determination of molecular weight of hyaluronic acid |
| WO2008089448A2 (en) | 2007-01-19 | 2008-07-24 | Cornell Presearch Foundation, Inc. | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis |
| CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CN102046195A (en) | 2008-04-02 | 2011-05-04 | 宏观基因有限公司 | HER2/neu-specific antibodies and methods of using same |
| WO2009128448A1 (en) | 2008-04-15 | 2009-10-22 | 和光純薬工業株式会社 | Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same |
| CN102378768A (en) | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | Bispecific anti-erbb-3/anti-c-met antibodies |
| CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| NZ701825A (en) | 2010-04-20 | 2016-06-24 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| CA2796633C (en) | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| DK2635607T3 (en) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| WO2012130831A1 (en) | 2011-03-29 | 2012-10-04 | Roche Glycart Ag | Antibody fc variants |
| EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| AU2012258706B2 (en) | 2011-05-24 | 2017-05-18 | Symic OA ApS | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use |
| EP2804586A4 (en) | 2012-01-19 | 2016-03-16 | Univ Johns Hopkins | Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications |
| SG10201607371UA (en) | 2012-04-20 | 2016-10-28 | Merus Nv | Methods and means for the production of ig-like molecules |
| WO2013163766A1 (en) | 2012-05-04 | 2013-11-07 | Cangene Corporation | ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC |
| CA2876096A1 (en) | 2012-08-02 | 2014-02-06 | Petra Rueger | Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof |
| EP2880169B1 (en) | 2012-08-02 | 2017-05-17 | F. Hoffmann-La Roche AG | Method for producing monomeric and multimeric molecules and uses thereof |
| TR201816437T4 (en) | 2012-08-07 | 2018-11-21 | Roche Glycart Ag | Composition comprising two antibodies designed to have reduced and increased effector function. |
| JP6385357B2 (en) * | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | Heterologous dimer of antibody heavy chain constant region, CH3 domain mutant pair that induces high-efficiency formation, production method and use thereof |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| WO2014150973A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
| WO2014177459A2 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| AR096891A1 (en) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME |
| UA117289C2 (en) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Multispecific antibodies |
| WO2015171822A1 (en) | 2014-05-06 | 2015-11-12 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
| CA2952727A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific nkp46 binding proteins |
| JP6576456B2 (en) | 2014-11-06 | 2019-09-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Fc region variants with modified FcRn binding properties and protein A binding properties |
| WO2016071376A2 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
| CN104628870A (en) * | 2015-02-04 | 2015-05-20 | 中国药科大学 | Human IL12Rbeta1-CHR protein and Fc fusion protein thereof |
| IL256989B (en) | 2015-08-07 | 2022-08-01 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| RU2770001C2 (en) | 2015-10-06 | 2022-04-14 | Риджентс Оф Дзе Юниверсити Оф Миннесота | Therapeutic compounds and methods |
| KR101851380B1 (en) | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | Method to generate CH3 domain mutant pairs of heterodimeric Fc using yeast mating and CH3 domain mutant pairs thereby |
| JP6983824B2 (en) | 2016-07-04 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | New antibody format |
| WO2018030806A1 (en) | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
| EP3511340A4 (en) | 2016-08-10 | 2020-03-18 | Ajou University Industry-Academic Cooperation Foundation | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
| US10550185B2 (en) | 2016-10-14 | 2020-02-04 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments |
| JP2019014449A (en) | 2017-07-10 | 2019-01-31 | トヨタ自動車株式会社 | Vehicular power transmission device |
| WO2019077092A1 (en) | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | Method for generating multispecific antibodies from monospecific antibodies |
| WO2020086758A1 (en) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
-
2017
- 2017-08-10 EP EP17839824.4A patent/EP3511340A4/en active Pending
- 2017-08-10 CN CN201780062851.0A patent/CN110267977A/en active Pending
- 2017-08-10 MX MX2019001651A patent/MX2019001651A/en unknown
- 2017-08-10 JP JP2019506697A patent/JP6993403B2/en active Active
- 2017-08-10 CA CA3033475A patent/CA3033475A1/en active Pending
- 2017-08-10 AU AU2017310163A patent/AU2017310163B2/en active Active
- 2017-08-10 SG SG11201901071TA patent/SG11201901071TA/en unknown
- 2017-08-10 KR KR1020170101594A patent/KR102050463B1/en active IP Right Grant
- 2017-08-10 US US16/323,839 patent/US10696722B2/en active Active
-
2019
- 2019-02-06 ZA ZA2019/00772A patent/ZA201900772B/en unknown
- 2019-02-08 MX MX2021010809A patent/MX2021010809A/en unknown
- 2019-11-25 KR KR1020190152270A patent/KR102416411B1/en active IP Right Grant
-
2020
- 2020-05-28 US US16/886,177 patent/US11078249B2/en active Active
- 2020-05-28 US US16/886,184 patent/US11692019B2/en active Active
-
2021
- 2021-03-03 JP JP2021033816A patent/JP7111855B2/en active Active
- 2021-11-26 AU AU2021273642A patent/AU2021273642A1/en active Pending
-
2022
- 2022-06-29 KR KR1020220079686A patent/KR102607285B1/en active Application Filing
- 2022-07-21 JP JP2022116329A patent/JP2022137288A/en active Pending
-
2023
- 2023-05-24 US US18/323,124 patent/US20230416325A1/en active Pending
- 2023-11-23 KR KR1020230164332A patent/KR102652247B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR102652247B1 (en) | 2024-03-29 |
| MX2019001651A (en) | 2019-09-04 |
| JP6993403B2 (en) | 2022-03-03 |
| JP2021088601A (en) | 2021-06-10 |
| US11692019B2 (en) | 2023-07-04 |
| KR102050463B1 (en) | 2019-11-29 |
| US11078249B2 (en) | 2021-08-03 |
| KR20180018419A (en) | 2018-02-21 |
| CA3033475A1 (en) | 2018-02-15 |
| US20230416325A1 (en) | 2023-12-28 |
| US10696722B2 (en) | 2020-06-30 |
| EP3511340A1 (en) | 2019-07-17 |
| KR102607285B1 (en) | 2023-12-01 |
| KR20220098108A (en) | 2022-07-11 |
| ZA201900772B (en) | 2023-07-26 |
| JP2019536734A (en) | 2019-12-19 |
| AU2021273642A1 (en) | 2021-12-16 |
| MX2021010809A (en) | 2021-10-01 |
| KR102416411B1 (en) | 2022-07-05 |
| JP7111855B2 (en) | 2022-08-02 |
| KR20190134564A (en) | 2019-12-04 |
| US20200362005A1 (en) | 2020-11-19 |
| KR20230163339A (en) | 2023-11-30 |
| JP2022137288A (en) | 2022-09-21 |
| CN110267977A (en) | 2019-09-20 |
| EP3511340A4 (en) | 2020-03-18 |
| BR112019002394A2 (en) | 2019-06-04 |
| US20200362004A1 (en) | 2020-11-19 |
| US20190169252A1 (en) | 2019-06-06 |
| AU2017310163A1 (en) | 2019-03-21 |
| AU2017310163B2 (en) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901071TA (en) | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same | |
| CL2019003390A1 (en) | Cytokine grafted antibody proteins and methods of use in cancer treatment | |
| PH12018500694A1 (en) | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins | |
| PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| EA201890456A1 (en) | NEW FUSED POLYPEPTIDE SPECIFIC WITH RESPECT TO LAG-3 AND PD-1 | |
| MX2021006017A (en) | Methods and compositions for treatment of disorders with follistatin polypeptides. | |
| MY169165A (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| MX2015011408A (en) | Il-33 antagonists and uses thereof. | |
| MX2021007184A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan. | |
| WO2015051030A3 (en) | Stabilized polypeptides and uses thereof | |
| MX2020007033A (en) | Anti-mct1 antibodies and uses thereof. | |
| MX2018002524A (en) | Pharmaceutical composition containing, as active ingredient, fusion protein in which tumor-penetrating peptide and anti-angiogenesis agent are fused, for preventing and treating cancer or angiogenesis-related diseases. | |
| MX2020014031A (en) | Heterodimeric proteins and uses thereof. | |
| EA201690159A1 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
| MX2020007018A (en) | Il-22 fc fusion proteins and methods of use. | |
| PH12020551500A1 (en) | Viscosity reduction of highly concentrated protein formulations | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| MX2020010568A (en) | Fused cyclic urea derivatives as crhr2 antagonist. | |
| MX2021005085A (en) | Antibody formulation. | |
| EA033269B1 (en) | INTERLEUKIN-1 BETA (IL-1β) INHIBITOR COMPOSITION AND USE THEREOF | |
| PH12019502850A1 (en) | AMIDE DERIVATIVES AS Nav1.7 AND Nav1.8 BLOCKERS | |
| SA518400042B1 (en) | Conjugate of finasteride with peptide | |
| PH12019500345A1 (en) | Conjugate of minoxidil and peptide | |
| EA201690826A1 (en) | RECOMBINANT GLYCOPROTEIDES AND THEIR APPLICATIONS | |
| MX2018013969A (en) | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist. |